Regeneron Pharmaceuticals

Open: 842.81 Close: 843.66 Change: 0.85

You're losing the opportunity of using an AI to get informed about Regeneron Pharmaceuticals Company Inc Stock.

Are looking for the most relevant information about Regeneron Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in Regeneron Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Regeneron Pharmaceuticals are: Regeneron, Pharmaceuticals, stock, share, price, trade, Inc, and the most common words in the summary are: regeneron, pharmaceutical, stock, job, watch, introduction, episode, . One of the sentences in the summary was: stock rises monday, still underperforms market - marketwatch.com. Other searches related …

Concept Map

Semantic Network

Stock Summary

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. The company's products include EYLEA injection to treat neovascular age-related macular degeneration.

Today's Summary

Regeneron Pharmaceuticals Inc. stock rises monday, still underperforms market - marketwatch.com. The dynamics of the instrument is expected.

Today's News

Regeneron Pharmaceuticals Inc (REGN) stock is higher by 0.28% while the S&P 500 is lower by -0.6% as of 2:37 PM on Friday, Oct 13. Regeneron shares are up today. Regeneron Pharmaceuticals Inc. stock rises monday, still underperforms market - marketwatch.com. New: Online Broker Comparison! Learn more about the best online brokers. Cantor Fitzgerald Raises Regeneron Pharmaceuticals Price Target to $850 from $800, Maintains Neutral Rating. 17 analysts have offered 12-month price targets. Regeneron Pharmaceuticals share price average forecast for Nov 2023 is: 719.662 The dynamics are negative. The dynamics of the instrument is expected with 4.029% volatility is expected. Pessimistic forecast: 715.82 Optimistic: 733.37 Regeneron. Regeneron Pharmaceuticals traded as high as $851.78 and last traded at $850.88, with a volume of 92717 shares traded. Argus upped their target price on Regeneron pharmaceuticals from $825.00 to $920.00 and gave the stock a “buy’s rating in a research note on Friday, September 15th.

Stock Profile

"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York."

Keywords

This document will help you to evaluate Regeneron Pharmaceuticals without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Regeneron Pharmaceuticals are: Regeneron, Pharmaceuticals, stock, share, price, trade, Inc, and the most common words in the summary are: regeneron, pharmaceutical, stock, job, watch, introduction, episode, . One of the sentences in the summary was: stock rises monday, still underperforms market - marketwatch.com. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #regeneron #pharmaceutical #stock #job #watch #introduction #episode.